Growth Metrics

Voyager Therapeutics (VYGR) Cash & Current Investments (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Cash & Current Investments for 11 consecutive years, with $196.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 26.34% to $196.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.4 million through Dec 2025, down 26.34% year-over-year, with the annual reading at $196.4 million for FY2025, 26.34% down from the prior year.
  • Cash & Current Investments hit $196.4 million in Q4 2025 for Voyager Therapeutics, down from $208.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $399.6 million in Q1 2024 to a low of $118.8 million in Q4 2022.
  • Historically, Cash & Current Investments has averaged $219.7 million across 5 years, with a median of $212.3 million in 2025.
  • Biggest five-year swings in Cash & Current Investments: soared 94.26% in 2023 and later crashed 41.89% in 2025.
  • Year by year, Cash & Current Investments stood at $132.5 million in 2021, then dropped by 10.33% to $118.8 million in 2022, then skyrocketed by 94.26% to $230.9 million in 2023, then increased by 15.51% to $266.7 million in 2024, then dropped by 26.34% to $196.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for VYGR at $196.4 million in Q4 2025, $208.9 million in Q3 2025, and $215.6 million in Q2 2025.